<?xml version='1.0' encoding='utf-8'?>
<document id="31874609"><sentence text="DDIGIP: predicting drug-drug interactions based on Gaussian interaction profile kernels." /><sentence text="A drug-drug interaction (DDI) is defined as a drug effect modified by another drug, which is very common in treating complex diseases such as cancer" /><sentence text=" Many studies have evidenced that some DDIs could be an increase or a decrease of the drug effect" /><sentence text=" However, the adverse DDIs maybe result in severe morbidity and even morality of patients, which also cause some drugs to withdraw from the market" /><sentence text=" As the multi-drug treatment becomes more and more common, identifying the potential DDIs has become the key issue in drug development and disease treatment" /><sentence text=" However, traditional biological experimental methods, including in vitro and vivo, are very time-consuming and expensive to validate new DDIs" /><sentence text=" With the development of high-throughput sequencing technology, many pharmaceutical studies and various bioinformatics data provide unprecedented opportunities to study DDIs" /><sentence text="" /><sentence text="In this study, we propose a method to predict new DDIs, namely DDIGIP, which is based on Gaussian Interaction Profile (GIP) kernel on the drug-drug interaction profiles and the Regularized Least Squares (RLS) classifier" /><sentence text=" In addition, we also use the k-nearest neighbors (KNN) to calculate the initial relational score in the presence of new drugs via the chemical, biological, phenotypic data of drugs" /><sentence text=" We compare the prediction performance of DDIGIP with other competing methods via the 5-fold cross validation, 10-cross validation and de novo drug validation" /><sentence text="" /><sentence text="In 5-fold cross validation and 10-cross validation, DDRGIP method achieves the area under the ROC curve (AUC) of 0" /><sentence text="9600 and 0" /><sentence text="9636 which are better than state-of-the-art method (L1 Classifier ensemble method) of 0" /><sentence text="9570 and 0" /><sentence text="9599" /><sentence text=" Furthermore, for new drugs, the AUC value of DDIGIP in de novo drug validation reaches 0" /><sentence text="9262 which also outperforms the other state-of-the-art method (Weighted average ensemble method) of 0" /><sentence text="9073" /><sentence text=" Case studies and these results demonstrate that DDRGIP is an effective method to predict DDIs while being beneficial to drug development and disease treatment" /><sentence text="" /></document>